Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

  • Net sales grew 6% (cc[1], +3% USD) mainly driven by:
    • Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications
    • Entresto more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwide
    • Promacta/Revolade USD 295 million (+32% cc), Tafinlar + Mekinist USD 291 million (+33% cc) and Jakavi USD 248 million (+27% cc) continued strong double-digit growth
    • AAA sales of USD 105 million, driven by the strong launch of …
/by

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

  • Net sales grew 6% (cc[1], +3% USD) mainly driven by:
    • Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications
    • Entresto more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwide
    • Promacta/Revolade USD 295 million (+32% cc), Tafinlar + Mekinist USD 291 million (+33% cc) and Jakavi USD 248 million (+27% cc) continued strong double-digit growth
    • AAA sales of USD 105 million, driven by the strong launch of …
/by